ArticleCell2021
Lrp1 is a host entry factor for Rift Valley fever virus.
Open access · greenAbstract read
In one paragraph
Article in Cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers.
0numbers the graph read from it
0cells of the map it votes in
96citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 123 citations in OpenAlex.
- Emerging threat of Oropouche virus: Clinical features, experimental models, and virulence.Virulence · 2026Review
- Pathogenicity of Rift Valley fever virus: Organ-specific clinical outcomes and hidden drivers of virulence - a narrative review.Virulence · 2026Review
- From Hepatitis to Encephalitis: Neuroinvasion and Antiviral Development in Rift Valley Fever Virus Infection.Pathogens (Basel, Switzerland) · 2026Review
- Opportunities and challenges for countermeasures against Rift Valley fever virus: A quintessential One Health pathogen.PLoS neglected tropical diseases · 2026Review
- Rift Valley fever virus infects trophoblast cell lines in an LRP1-dependent manner.The Journal of general virology · 2026Article
- Neutralizing Antibodies Against Rift Valley Fever Virus: Current Status and Advances.Vaccines · 2026Review
- Intranasal infection of Rift Valley fever virus in the ferret model suggests multiple routes of neuroinvasion with consequential encephalitis and ophthalmitis.Scientific reports · 2026Article
- Nairobi sheep disease virus: an emerging threat with unresolved pathogenesis and zoonotic potential.Journal of virology · 2026Review
- Karimabad virus: A neglected sandfly-borne pathogen.Medicine · 2026Review
- Alveolar type 2 cell LRP1 is needed for surfactant phospholipid metabolism and pulmonary function in mice.Journal of lipid research · 2026Article
- Spatial transcriptomics and single-nucleus RNA sequencing reveal rAAV2- and rAAV9-specific transduction signatures in the mouse liver.Gene therapy · 2026Article
- Integrative structural analysis of the human LRP2-LRPAP1 complex reveals multiple regulatory sites.Communications biology · 2026Article
- Design of a neutralizing and protective pan-encephalitic alphavirus receptor decoy protein.Science translational medicine · 2026Article
- Review
- Elucidating genes sufficient for viral entry into cells through sequential genome-wide CRISPR activation screens.bioRxiv : the preprint server for biology · 2026Article
- Structural basis for recognition of Rift Valley fever virus Gn protein by a human neutralizing monoclonal antibody with a kappa light chain.PLoS pathogens · 2026Article
- Potential Mechanisms Underlying Bleeding During Infection With Hemorrhagic Fever Viruses.Arteriosclerosis, thrombosis, and vascular biology · 2026Review
- Article
- CRISPR-based screening of host factors in veterinary viral infections: from target discovery to host-directed antiviral strategies.Frontiers in veterinary science · 2026Review
- LRP1 facilitates Jamestown Canyon virus infection of neurons.Journal of virology · 2025Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
34 authors at 5 institutions in 2 countries.
Safder S GanaieDepartment of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
Madeline M SchwarzCenter for Vaccine Research, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; Department of Infectious Diseases and Microbiology, School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.
Cynthia M McMillenCenter for Vaccine Research, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; Department of Infectious Diseases and Microbiology, School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.
David A PriceDepartment of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
Annie X FengDepartment of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
Joseph R AlbeCenter for Vaccine Research, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Wenjie WangDepartment of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
Shane MierschThe Donnelly Centre, University of Toronto, Toronto, ON, Canada.
Anthony OrvedahlDepartment of Pediatrics, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
Aidan R ColeDepartment of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
Monica F SentmanatGenome Engineering and iPSC Center (GEiC), Department of Genetics, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
Nawneet MishraDepartment of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
Devin A BoylesCenter for Vaccine Research, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Zachary T KoenigCenter for Vaccine Research, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; Department of Infectious Diseases and Microbiology, School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.
Michael R KujawaCenter for Vaccine Research, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; Department of Infectious Diseases and Microbiology, School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.
Matthew A DemersCenter for Vaccine Research, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Ryan M HoehlCenter for Vaccine Research, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Austin B MoyleDepartment of Chemistry, Washington University in St. Louis, St. Louis, MO, USA.
Nicole D WagnerDepartment of Chemistry, Washington University in St. Louis, St. Louis, MO, USA.
Sarah H StubbsDepartment of Microbiology, Harvard Medical School, Boston, MA, USA.
Lia CardarelliThe Donnelly Centre, University of Toronto, Toronto, ON, Canada.
Joan TeyraThe Donnelly Centre, University of Toronto, Toronto, ON, Canada.
Anita McElroyCenter for Vaccine Research, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; Department of Pediatrics, Division of Pediatric Infectious Disease, University of Pittsburgh, Pittsburgh, PA, USA.
Michael L GrossDepartment of Chemistry, Washington University in St. Louis, St. Louis, MO, USA.
Sean P J WhelanDepartment of Molecular Microbiology, Washington University in St. Louis, St. Louis, MO, USA.
John DoenchBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Xiaoxia CuiGenome Engineering and iPSC Center (GEiC), Department of Genetics, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
Tom J BrettDepartment of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
Sachdev S SidhuThe Donnelly Centre, University of Toronto, Toronto, ON, Canada.
Herbert W VirginDepartment of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA; Current address: Vir Biotechnology, San Francisco, CA, USA.
Takeshi EgawaDepartment of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
Daisy W LeungDepartment of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA; Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
Gaya K AmarasingheDepartment of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA. Electronic address: gamarasinghe@wustl.edu.
Amy L HartmanCenter for Vaccine Research, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; Department of Infectious Diseases and Microbiology, School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: hartman2@pitt.edu.
Washington University in St. Louis · USUniversity of Pittsburgh · USUniversity of Toronto · CABroad Institute · USHarvard University · US
Funding
RP5: Chemical proteomic discovery of small-molecule probes for autophagy proteinsU19AI142784 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI CRAVATT, BENJAMIN F · 2019 to 2023
$36.9MVirology BSL4 CoreP01AI120943 · NIAID · WASHINGTON UNIVERSITY · PI ROBERT A DAVEY · 2016 to 2026
$30.2MTrainingP41GM103422 · NIGMS · WASHINGTON UNIVERSITY · PI YARASHESKI, KEVIN E · 2012 to 2019
$12.0MRNA Processing in Non-Segmented Minus-Strand RNA VirusesR37AI059371 · NIAID · WASHINGTON UNIVERSITY · PI WHELAN, SEAN PJ · 2015 to 2024
$5.4MImmunology of Infectious DiseaseT32AI060525 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JoAnne L. Flynn · 2005 to 2026
$5.3MThe transcription factor c-MYC in lymphocyte expansion and restriction of stemnessR01AI130152 · NIAID · WASHINGTON UNIVERSITY · PI Takeshi Egawa · 2017 to 2026
$4.6MNovel VP30-host Interactions that Negatively Regulate Ebola Virus InfectionR01AI143292 · NIAID · WASHINGTON UNIVERSITY · PI AMARASINGHE, GAYA K., BASLER, CHRISTOPHER F · 2019 to 2023
$4.0MIdentification and Characterization of Entry Factors Critical for Rift Valley Fever Virus Infection and PathogenesisR01AI161765 · NIAID · WASHINGTON UNIVERSITY · PI AMARASINGHE, GAYA K., HARTMAN, AMY L · 2021 to 2025
$3.7MLive-attenuated Rift Valley fever vaccines: comparative mechanisms of trans-placental transmission and vaccine efficacy for developing fetusesR01AI150792 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HARTMAN, AMY L · 2020 to 2025
$3.7MA Biomedical Mass Spectrometry Resource: Ongoing Driving Biomedical ProjectsR24GM136766 · NIGMS · WASHINGTON UNIVERSITY · PI GROSS, MICHAEL L · 2020 to 2022
$2.3MMulti-platform High Throughput Screens for Filoviral Replication InhibitorsR01AI123926 · NIAID · WASHINGTON UNIVERSITY · PI AMARASINGHE, GAYA K. · 2016 to 2018
$2.1MSTRUCTURAL BASIS FOR IMMUNE EVASION BY RSV NON-STRUCTURAL PROTEINSR01AI107056 · NIAID · WASHINGTON UNIVERSITY · PI LEUNG, DAISY W · 2013 to 2017
$1.9MNIAID NIH HHS K08 AI144033NIAID NIH HHS P01 AI120943NIAID NIH HHS R01 AI107056NIAID NIH HHS R01 AI123926NIAID NIH HHS R01 AI130152NIAID NIH HHS R01 AI143292NIAID NIH HHS R01 AI150792NIAID NIH HHS R01 AI161765NIAID NIH HHS R21 AI163603NIAID NIH HHS R37 AI059371NIAID NIH HHS T32 AI060525NIAID NIH HHS T32 AI106688NIAID NIH HHS U19 AI142784NIGMS NIH HHS P41 GM103422NIGMS NIH HHS R24 GM136766NINDS NIH HHS R01 NS101100
Abstract
Rift Valley fever virus (RVFV) is a zoonotic pathogen with pandemic potential. RVFV entry is mediated by the viral glycoprotein (Gn), but host entry factors remain poorly defined. Our genome-wide CRISPR screen identified low-density lipoprotein receptor-related protein 1 (mouse Lrp1/human LRP1), heat shock protein (Grp94), and receptor-associated protein (RAP) as critical host factors for RVFV infection. RVFV Gn directly binds to specific Lrp1 clusters and is glycosylation independent. Exogenous addition of murine RAP domain 3 (mRAP
Indexed as
Host-Pathogen InteractionsVirus InternalizationAnimalsAntibody SpecificityBase SequenceBrainCell MembraneCells, CulturedCRISPR-Cas SystemsGlycoproteinsGlycosaminoglycansGlycosylationHumansLDL-Receptor Related Protein-Associated ProteinLigandsLow Density Lipoprotein Receptor-Related Protein-1endoplasminGlycoproteinsGlycosaminoglycansLDL-Receptor Related Protein-Associated ProteinLigandsLow Density Lipoprotein Receptor-Related Protein-1Membrane GlycoproteinsCRISPR screenLrp1Rift Valley fever virusviral entry
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.